Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
NCTID
NCT00976352
(View at clinicaltrials.gov)
Description
Pompe disease is an inherited condition of acid alpha-glucosidase (GAA) deficiency resulting in lysosomal accumulation of glycogen in all tissues. Glycogen accumulation leads to muscle dysfunction and profound muscle weakness. A wide spectrum of disease is characteristic and the most severe patients have cardiorespiratory failure, often fatal in the first two years of life. Researchers have developed a way to introduce the normal GAA gene into muscle cells with the expectation that the GAA protein will be produced at levels sufficient to reduce glycogen accumulation. This study will evaluate the safety of the experimental gene transfer procedure in individuals with GAA deficiency. The study will also determine what dose may be required to achieve improvement in measures of respiratory function.
(Show More)
Development Status
Inactive
Indication
Glycogen Storage Disease Type 2 (Pompe Disease)
Disease Ontology Term
DOID:2752
Compound Name
AAV1-CMV-hGAA
Sponsor
University of Florida
Funder Type
Other
Recruitment Status
Completed
Enrollment Count
9
Results Posted
View Results
Therapy Information
Target Gene/Variant
GAA
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intramuscular (diaphragm)
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV2/1
Editor Type
none
Dose 1
1E12 vg (n=3)
Dose 2
5E12 vg (n=6)
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2009-07-13
Completion Date
2015-12
Last Update
2018-09-14
Participation Criteria
Eligible Age
2 Years - 18 Years
Standard Ages
Child, Adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
1
Locations
United States
Regulatory Information
Has US IND
True
FDA Designations
Recent Updates
Sponsors of this trial redesigned the drug product by changing the capsid (AAV2/1 -> AAV2/9) and promoter (CMV->DES), and site of administration (diaphragm -> tibialis anterior), updated trial record is NCT02240407
Resources/Links
Clinical Publications
Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes
Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity
Advancements in AAV-mediated Gene Therapy for Pompe Disease
Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease
Preclinical Publications
Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors
Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia
Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease
Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors
Protocol
Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV-GAA) Gene Vector in Patients with Pompe Disease
Related NCTID
Phase 1: NCT02240407 (second generation product)